Morgan Stanley & Co. LLCCall Option Transaction • February 29th, 2016 • Novavax Inc • Biological products, (no disgnostic substances) • New York
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between Morgan Stanley & Co. LLC (“Dealer”) and Novavax, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for the Transaction.
JPMorgan Chase Bank, National Association London Branch Canary Wharf London E14 5JPCall Option Transaction • February 29th, 2016 • Novavax Inc • Biological products, (no disgnostic substances) • New York
The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between JPMorgan Chase Bank, National Association, London Branch (“Dealer”) and Novavax, Inc. (“Counterparty”) as of the Trade Date specified below (the “Transaction”). This letter agreement constitutes a “Confirmation” as referred to in the ISDA Master Agreement specified below. This Confirmation shall replace any previous agreements and serve as the final documentation for the Transaction.
ContractDirector Fee Deferral Agreement • February 29th, 2016 • Novavax Inc • Biological products, (no disgnostic substances) • Maryland
THIS AGREEMENT is entered into as of December ___, 2015 by and between Novavax, Inc., a Delaware corporation (the “Company”), and [●] (the “Director”).
